{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"After completion of Phase 1 Dose Escalation of this study the sponsor decided not to proceed with Phase 2a due to strategic reasons and hence no participants were enrolled for Phase 2a.","groups":[{"description":"Participants received modakafusp alfa 80 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 60 weeks.","id":"OG000","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 80 mg + Daratumumab"},{"description":"Participants received modakafusp alfa 120 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 48 weeks.","id":"OG001","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 120 mg + Daratumumab"},{"description":"Participants received modakafusp alfa 240 mg, infusion, IV, Q4W with daratumumab 1800 mg, SC, QW in Cycles 1 and 2, Q2W in Cycles 3 to 6, and Q4W thereafter in each 28-day treatment cycle until disease progression or up to 36 weeks.","id":"OG002","title":"Phase 1 (Dose Escalation) Modakafusp Alfa 240 mg + Daratumumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity-evaluable Population included participants who received at least 1 dose of modakafusp alfa in combination with daratumumab SC (partial or complete) with a baseline assessment \\& at least 1 postbaseline immunogenicity assessment. No data was collected for this outcome measure due to study termination. Overall number of participants analyzed is the number of participants with data available for analyses.","reportingStatus":"POSTED","timeFrame":"Up to 15.9 months","title":"Phase 1 and Phase 2a: Number of Participants With Anti-drug Antibodies (ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}